Pancreatic cancer is hard to treat because it is surrounded by dense supportive tissue that blocks chemotherapy. The most abundant cells in this tissue are cancer-associated fibroblasts (CAFs), which strongly influence how tumors grow, spread, and resist treatment. Rather than being just passive barriers, CAFs actively shape the tumor environment.
Researchers have found that CAFs exist in different types with opposing roles. Some can help restrain tumor growth, while others release inflammatory signals that promote cancer progression and suppress immune responses. Certain CAF subtypes are linked to poor survival, showing that targeting the wrong fibroblasts could worsen the disease.
Because of this, new therapies aim to selectively target harmful CAFs or reprogram them into a quieter, less active state instead of removing them entirely. Approaches include calming CAFs with vitamin-based drugs, breaking down the dense tissue to improve drug delivery, and blocking CAF-cancer signaling pathways. These strategies highlight a shift toward more precise, balanced treatments for pancreatic cancer.